GlassScriptPhysician profile
Sheila Dini
NPI 1003187709
$1,385.59
in general payments reported to CMS, 2019-2025
26 companies · $339 in 2025
The $339 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $155 · 2022: $16.80 · 2023: $381 · 2024: $494 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,139 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,138.81 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $154.98 | 2021-2024 | |
| Daiichi Sankyo INC. | $139.79 | 2024-2025 | Enhertu, Injectafer, Datroway |
| Karyopharm Therapeutics INC. | $124.98 | 2023 | Xpovio |
| Janssen Biotech, INC. | $92.22 | 2023-2024 | Darzalex, Tecvayli, Talvey |
| Glaxosmithkline, LLC. | $89.83 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Takeda Pharmaceuticals U.S.A., INC. | $85.85 | 2023-2025 | Ninlaro, Alunbrig |
| Coherus Oncology, INC. | $75.00 | 2021 | |
| Beigene USA, INC. | $72.03 | 2023 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $69.54 | 2023-2024 | Lynparza, Tagrisso |
| Gilead Sciences, INC. | $66.18 | 2024 | |
| Abbvie INC. | $49.91 | 2023-2024 | |
| Genentech USA, INC. | $40.64 | 2024-2025 | Polivy, Lunsumio, Columvi |
| Blueprint Medicines Corporation | $32.77 | 2025 | Ayvakit |
| Array Biopharma INC | $30.82 | 2024-2025 | Mektovi, Tukysa, Braftovi |
| Astellas Pharma US INC | $30.09 | 2025 | Vyloy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $25.61 | 2023 | |
| Lilly USA, LLC | $24.79 | 2024 | Jaypirca, Retevmo, Verzenio |
| Bayer Healthcare Pharmaceuticals INC. | $23.42 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $23.07 | 2024 | Libtayo |
| Janssen Pharmaceuticals, INC | $22.72 | 2025 | Erleada |
| Celgene Corporation | $21.79 | 2023 | Pomalyst |
| Pharmaessentia USA Corporation | $20.41 | 2025 | Besremi |
| Servier Pharmaceuticals LLC | $19.31 | 2024 | |
| Novartis Pharmaceuticals Corporation | $18.75 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $16.82 | 2025 | |
| Emd Serono, INC. | $14.27 | 2023 | Bavencio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheila Dini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.